mast
cell
two
distinct
phase
activ
immedi
degranul
result
releas
presynthes
mediat
delay
secret
secondari
de
novo
synthes
mediat
delay
secret
secondari
de
novo
effector
molecul
produc
mast
cell
segreg
two
class
prostaglandin
eicosanoid
releas
within
minut
activ
cytokin
chemokin
growth
factor
releas
within
hour
stimul
figur
togeth
mast
cell
output
increas
epitheli
endotheli
cell
permeabl
activ
state
togeth
chemotact
molecul
result
increas
inflammatori
cell
recruit
infect
tissu
figur
mast
cell
granul
contain
histamin
amin
serotonin
antimicrobi
peptid
proteas
tryptas
chymas
bound
either
heparin
chondroitin
sulfat
electrostat
interact
upon
stimul
granul
releas
cell
via
calciumdepend
exocytosi
process
expel
granul
either
discharg
store
mediat
immedi
environ
intact
granul
travel
bloodstream
lymphat
act
signal
mechan
activ
recruit
cell
infect
tissu
histamin
potent
inflammatori
molecul
increas
vascular
permeabl
induc
vasodil
stimul
bronchial
smooth
muscl
contract
inflammatori
cytokin
promot
local
system
inflamm
enhanc
neutrophil
recruit
site
infect
granul
proteas
capabl
increas
vascular
permeabl
enhanc
recruit
neutrophil
site
inflamm
act
directli
detoxifi
toxic
protein
interestingli
local
homeostat
cytokin
milieu
tissu
modul
precis
granul
compon
allow
mast
cell
adapt
local
environ
mount
tissu
appropri
inflammatori
respons
follow
activ
mast
cell
uniqu
replenish
granul
usual
within
week
activ
abil
regranul
allow
mast
cell
tailor
composit
granul
thu
prepar
reinfect
figur
immedi
mast
cell
degranul
respons
arachidon
aciddepend
inflammatori
mediat
leukotrien
prostaglandin
rapidli
produc
releas
mast
cell
due
enzymat
rather
transcript
chang
within
mast
cell
lipid
mediat
contribut
local
vascular
permeabl
tissu
edema
recruit
neutrophil
inflammatori
cell
final
de
novo
synthes
cytokin
chemokin
growth
factor
releas
hour
follow
activ
transcript
translat
upregul
multitud
cytokin
chemokin
growth
factor
releas
mast
cell
includ
de
novo
synthes
vegf
mediat
activ
tissueresid
cell
recruit
addit
effector
leukocyt
lymphocyt
maintain
inflammatori
state
prolong
time
conclus
releas
numer
chemotact
factor
vasodil
mast
cell
optim
rapid
initi
propag
acut
inflammatori
respons
degranul
product
bioactiv
lipid
secret
cytokin
chemokin
result
leukocyt
lymphocyt
infiltr
help
maintain
inflammatori
state
infect
persist
figur
addit
tissueresid
mast
cell
mast
cell
progenitor
recruit
site
acut
chronic
inflamm
recruit
mast
cell
progenitor
regul
begin
understood
mucos
mast
cell
mmc
domin
type
mast
cell
lung
develop
bone
marrow
mast
cell
progenitor
asthma
model
follow
aerosol
challeng
ovalbumin
mast
cell
progenitor
rapidli
recruit
lung
peak
day
challeng
ovalbumininduc
allerg
airway
inflammatori
diseas
multipl
pathway
critic
mast
cell
progenitor
accumul
lung
integrin
regul
migrat
mast
cell
progenitor
lung
interact
moreov
express
radioresist
cell
popul
import
regul
mast
cell
progenitor
recruit
lung
like
regul
pulmonari
endothelium
nkt
cell
also
abl
induc
mast
cell
progenitor
accumul
lung
depend
pathway
final
prostaglandin
leukotrien
highli
produc
mast
cell
shown
enhanc
chemotaxi
mast
cell
progenitor
addit
wellelucid
role
allerg
airway
diseas
strong
evid
accumul
mast
cell
intestin
tract
helminth
infect
furthermor
mast
cell
precursor
appear
accumul
site
viral
infect
includ
iav
sendai
viru
infecti
bursal
diseas
viru
ibdv
newcastl
diseas
viru
ndv
accumul
mast
cell
progenitor
occur
either
mast
cell
degranulationdepend
independ
manner
therefor
mast
cell
activ
result
local
accumul
mast
cell
infect
tissu
augment
role
cell
play
infect
figur
mast
cell
express
larg
array
innat
cell
surfac
cytosol
receptor
mediat
activ
integr
cell
initi
appropri
immun
respons
infecti
agent
notabl
mast
cell
express
larg
array
fc
receptor
includ
mast
cell
also
abl
respond
wide
varieti
patternrecognit
receptor
prr
includ
tolllik
receptor
tlr
nodlik
receptor
nlr
retinoicacid
induc
gene
receptor
rlr
ctype
lectin
receptor
clr
play
essenti
role
innat
immun
detect
conserv
molecular
pattern
express
pathogen
mast
cell
also
activ
engag
complement
receptor
integrin
lastli
mast
cell
respond
pathogen
indirectli
signal
pathway
thu
mast
cell
capabl
respond
broad
rang
pathogenderiv
pathogeninduc
stimuli
figur
interestingli
mast
cell
respond
uniformli
input
stimuli
exampl
signal
lead
strong
proinflammatori
cytokin
respons
limit
mast
cell
degranul
convers
signal
induc
inflammatori
cytokin
respons
mast
cell
degranul
mast
cell
activ
therefor
import
rheostat
immun
system
like
modul
appropri
respons
howev
aberr
activ
prolong
activ
may
elicit
tissu
immunopatholog
mast
cell
frequent
recogn
detriment
role
allerg
respons
follow
initi
exposur
antigen
ag
activ
b
cell
undergo
class
switch
result
secret
ige
highaffin
ige
receptor
express
surfac
mast
cell
bind
fc
portion
ige
sensit
mast
cell
upon
subsequ
exposur
polyval
ag
crosslink
surfac
bound
ige
result
mast
cell
degranul
product
bioactiv
lipid
cytokin
chemokin
mast
cell
also
recogn
role
asthma
asthma
pleomorph
diseas
character
recurr
airway
restrict
short
breath
wheez
cough
within
asthma
patient
includ
atop
allerg
nonatop
intrins
number
local
phenotyp
mast
cell
alter
repeat
activ
pulmonari
mast
cell
allergen
result
mast
cell
like
degranul
compar
nonasthmat
patient
overal
mast
cell
respons
contribut
bronchial
constrict
chronic
inflamm
tissu
remodel
typic
asthma
patient
welldocu
infect
respiratori
virus
includ
iav
rhinoviru
respiratori
syncyti
viru
rsv
often
exacerb
asthma
upper
respiratori
tract
infect
frequent
lead
hospit
admiss
asthma
patient
interestingli
asthma
common
comorbid
among
hospit
patient
iav
pandem
state
hyperrespons
asthmat
patient
well
increas
level
inflammatori
molecul
eg
histamin
leukotrien
believ
contribut
asthmat
exacerb
viral
infect
thu
critic
understand
interact
mast
cell
virus
host
chronic
inflammatori
condit
alter
mast
cell
number
function
pandem
isol
emerg
highli
pathogen
avian
strain
iav
capabl
induc
robust
inflammatori
respons
caus
signific
damag
within
lung
ultim
restructur
lung
architectur
human
experiment
infect
iav
detect
histamin
metabolit
correl
clinic
symptom
moreov
emerg
data
murin
model
iav
suggest
link
mast
cell
recruit
activ
lung
immunopatholog
follow
inocul
mous
adapt
strain
iav
mice
develop
signific
patholog
inflamm
recapitul
clinic
observ
pandem
human
mice
infect
nonadapt
strain
mice
inocul
mouseadapt
iav
enrich
gene
activ
macrophag
neutrophil
mast
cell
observ
compar
mice
inocul
nonpathogen
strain
moreov
observ
made
infect
recombin
thu
appear
earli
accumul
activ
macrophag
neutrophil
mast
cell
correl
immunopatholog
associ
pandem
iav
infect
prior
transcriptom
studi
suggest
increas
mast
cell
densiti
observ
nasal
mucosa
trachea
lung
parenchyma
mediastin
lymph
node
follow
infect
highli
patholog
isol
data
demonstr
mast
cell
increas
lung
mice
highli
patholog
iav
infect
role
inflammatori
respons
induc
iav
remain
elus
regard
recent
data
demonstr
mast
cell
play
detriment
role
iav
infect
strain
specif
manner
specif
follow
infect
mice
lack
mast
cell
exhibit
reduct
weight
loss
lung
patholog
pulmonari
inflamm
compar
wildtyp
mice
importantli
mast
cell
reconstitut
mice
weight
loss
inflammatori
respons
restor
wildtyp
level
studi
use
highli
pathogen
viru
mice
administ
ketotifen
mast
cell
stabil
agent
demonstr
reduc
lung
inflamm
epitheli
cell
apoptosi
untreat
mice
furthermor
combin
therapi
ketotifen
oseltamivir
na
inhibitor
improv
surviv
better
either
drug
alon
taken
togeth
data
show
mast
cell
contribut
patholog
observ
iav
infect
mice
newli
emerg
zoonot
strain
highli
pathogen
iav
also
present
high
cellular
infiltr
damag
within
lung
mice
suggest
mast
cell
activ
mast
cell
particip
immunopatholog
elicit
emerg
zoonot
iav
isol
remain
seen
human
infect
dengu
viru
result
wide
rang
patholog
sever
form
dengu
viru
induc
dengu
hemorrhag
fever
dengu
shock
syndrom
character
increas
vascular
permeabl
product
crossreact
antibodi
primari
infect
lead
sever
diseas
upon
secondari
infect
heterolog
serotyp
urin
blood
infect
patient
display
elev
level
histamin
presenc
vasoact
factor
increas
serum
level
chymas
mast
cell
specif
enzym
mediat
releas
mast
cell
numer
studi
examin
role
mast
cell
play
dengu
viru
infect
upon
exposur
dengu
viru
induc
degranul
cytokin
product
mast
cell
mast
cell
deriv
granul
proteas
increas
vascular
permeabl
synthesi
releas
recruit
nk
cell
cell
site
infect
mast
cell
defici
mice
show
reduct
symptom
demonstr
mast
cell
play
import
role
dengu
virusinduc
immunopatholog
moreov
administr
mast
cell
stabil
drug
cromolyn
ketotifen
antagonist
montelukast
result
reduc
vascular
leakag
compar
untreat
mice
current
data
suggest
earli
infect
mast
cell
activ
dengu
viru
benefici
recruit
nk
cell
promot
viral
clearanc
howev
widespread
mast
cell
activ
detriment
increas
vascular
leakag
lead
sever
form
dengueinduc
diseas
murin
model
presenc
nonneutr
igg
enhanc
mast
cell
degranul
dengu
infect
interact
therefor
dengu
viru
activ
mast
cell
directli
yet
unidentifi
mechan
indirectli
zoonot
transmiss
hantaviru
human
result
hemorrhag
fever
renal
syndrom
hantaviru
cardiopulmonari
syndrom
character
increas
vascular
permeabl
thrombocytopenia
patient
hemorrhag
fever
renal
syndrom
exhibit
significantli
elev
histamin
level
indic
possibl
role
mast
cell
potenti
syndrom
endotheli
cell
epitheli
cell
dendrit
cell
permiss
hantaviru
infect
vitro
recent
evid
suggest
mast
cell
also
suscept
viru
inocul
vivo
differenti
mast
cell
result
product
infect
mast
cell
activ
though
abil
hantaviru
directli
induc
degranul
known
furthermor
abil
variou
strain
hantaviru
infect
replic
within
mast
cell
directli
correl
pathogen
strain
thu
mast
cell
may
import
factor
hantavirusinduc
diseas
sendai
viru
respiratori
parainfluenza
viru
highli
transmiss
rodent
swine
neonat
rat
sendai
viru
caus
viral
bronchiol
airway
hyperrespons
associ
elev
level
bronchiolar
mast
cell
eosinophil
elev
number
bronchiolar
mast
cell
observ
sendai
viru
infect
result
prolifer
tissueresid
mast
cell
recruit
mast
cell
progenitor
airway
sendai
viru
also
infect
human
mast
cell
result
activ
releas
major
granul
compon
detect
human
mast
cell
histamin
releas
rat
tryptas
releas
pig
detect
follow
sendai
viru
challeng
follow
sendai
viru
infect
human
mast
cell
produc
type
iii
interferon
implic
asthma
exacerb
interestingli
rat
model
anim
previous
infect
sendai
viru
subsequ
sensit
ovalbumin
later
display
heighten
allerg
airway
inflammatori
cell
reaction
thu
mast
cell
import
contributor
inflammatori
respons
parainfluenza
virus
particip
patholog
role
allerg
airway
diseas
ibdv
contagi
diseas
high
mortal
rate
impact
poultri
industri
worldwid
ibdv
infect
chicken
increas
inflammatori
lesion
lead
suscept
secondari
infect
mast
cell
number
increas
site
infect
ibdv
moreov
mast
cell
activ
mast
cell
tryptas
accumul
infect
tissu
treatment
ketotifen
decreas
mast
cell
number
infect
bird
also
correl
reduc
injuri
infect
without
alter
express
ibdv
ag
thu
reduc
releas
mast
cell
mediat
one
decreas
mast
cell
accumul
infect
tissu
ultim
decreas
tissu
damag
increas
surviv
ibdv
infect
ndv
anoth
highli
contagi
poultri
diseas
infect
gastrointestin
tract
result
high
mortal
econom
loss
similar
ibdv
mast
cell
found
around
ndv
lesion
infect
correl
increas
mast
cell
tryptas
level
tissu
chicken
pretreat
ketotifen
show
reduct
tissu
damag
ndv
infect
thu
similar
ibdv
inhibit
mast
cell
mediat
reduc
mast
cell
accumul
infect
tissu
decreas
tissu
damag
increas
surviv
follow
ndv
infect
porcin
reproduct
respiratori
syndrom
viru
prrsv
associ
high
mortal
pig
infect
low
pathogen
prrsv
lpprrsv
result
minim
histopatholog
chang
mortal
contrast
infect
high
pathogen
strain
prrsv
hpprrsv
result
signific
mortal
associ
extens
tissu
damag
within
lung
pig
infect
hpprrsv
display
signific
respiratori
distress
associ
pulmonari
lesion
character
inflammatori
cell
infiltr
interstiti
alveolar
edema
hemorrhag
observ
follow
lppprsv
infect
infect
hpprrsv
result
higher
viru
titer
higher
level
proinflammatori
cytokin
immun
cell
infiltr
includ
neutrophil
mononuclear
phagocyt
mast
cell
histamin
significantli
increas
serum
hpprrsv
infect
pig
mediat
play
import
role
increas
blood
vessel
permeabl
diseas
sever
dengu
viru
infect
like
contribut
increas
lung
edema
hemorrhag
observ
hpprrsv
pathogen
nonpathogen
hantaviru
nucleoprotein
detect
mast
cell
addit
human
mast
cell
line
permiss
dengu
viru
presenc
human
dengu
viru
immun
sera
data
demonstr
highli
pathogen
virus
infect
mast
cell
rsv
activ
mast
cell
result
product
cytokin
chemokin
includ
type
interferon
rsv
ag
detect
primari
cord
blood
mast
cell
human
mast
cell
line
follow
infect
howev
similar
mani
pathogen
virus
mast
cell
infect
result
releas
infecti
progeni
virion
respiratori
epitheli
cell
primari
target
iav
replic
iav
infect
wide
rang
cell
includ
endotheli
cell
macrophag
dendrit
cell
mast
cell
mast
cell
iav
abl
mediat
viral
entri
larg
appear
undergo
abort
infect
inocul
murin
bone
marrow
deriv
mast
cell
bmdmc
result
de
novo
express
viral
protein
produc
new
infecti
particl
interestingli
treatment
murin
bmdmc
anoth
isol
result
detect
express
hand
infect
human
mast
cell
line
lad
human
cord
blood
deriv
mast
cell
strain
result
viral
mrna
protein
synthesi
produc
de
novo
infecti
particl
contrast
recent
data
demonstr
murin
mastocytoma
cell
line
product
infect
produc
infecti
viru
first
h
infect
measur
qrtpcr
hemagglutin
assay
plaqu
form
assay
differ
like
reflect
differ
type
mast
cell
use
studi
infecti
dose
viru
overal
data
demonstr
iav
dengu
viru
rsv
hantaviru
least
bind
enter
mast
cell
like
import
mast
cell
activ
studi
need
understand
fine
specif
virus
specif
differ
iav
isol
distinct
mast
cell
popul
cellular
factor
may
present
popul
limit
iav
propag
mast
cell
express
wide
rang
prr
allow
cell
respond
varieti
stimuli
includ
bacteria
parasit
fungi
virus
figur
rigi
cytosol
receptor
detect
iav
rna
mani
singl
strand
rna
virus
rigi
detect
vrna
signal
mitochondri
adaptor
mav
result
antivir
respons
mast
cell
signal
rigimav
pathway
import
secondari
respons
iav
immedi
degranul
mast
cell
viru
recognit
rigi
mast
cell
also
import
dengu
viru
vesicular
stomat
viru
vsv
infect
howev
studi
suggest
rigi
depend
respons
mast
cell
significantli
contribut
pulmonari
immunopatholog
associ
iav
infect
graham
obar
unpublish
observ
rather
mast
cell
degranul
appear
domin
mediat
immunopatholog
addit
rigi
detect
also
import
recognit
iav
type
reoviru
rsv
vsv
ndv
murin
bmdmc
product
secondari
mast
cell
mediat
moreov
viral
recognit
oligoadenyl
synthas
oa
particip
initi
secondari
respons
mast
cell
induc
vsv
thu
detect
viral
nucleic
acid
appear
central
product
de
novo
synthes
mast
cell
mediat
follow
viral
infect
altern
infect
detect
indirectli
mast
cell
occur
herp
simplex
viru
hsv
infect
epitheli
cell
secret
turn
detect
mast
cell
result
secret
without
degranul
mast
cell
degranul
appear
play
critic
role
regul
mast
cell
depend
inflamm
follow
iav
infect
also
number
viral
system
mast
cell
degranul
inhibitor
ketotifen
reduc
inflamm
respons
iav
infect
mice
inflamm
associ
ibdv
ndv
poultri
addit
mast
cell
stabil
use
cromolyn
limit
dengu
viru
induc
immunopatholog
togeth
data
strongli
support
role
mast
cell
degranul
mast
celldepend
inflammatori
respons
highli
virul
viral
infect
thu
appear
critic
understand
virus
drive
mast
cell
degranul
appropri
target
cell
pharmacolog
mast
cell
degranul
respons
viral
infect
remain
larg
unknown
degranul
still
occur
respons
infect
rigidefici
bmdmc
demonstr
degranul
rigiindepend
respons
degranul
occur
within
min
follow
treatment
iav
prr
andor
earli
signal
event
necessari
viru
attach
andor
entri
process
like
import
regul
mast
cell
degranul
dengu
viru
degranualt
mast
cell
occur
prior
rigi
signal
moreov
uvinactiv
dengu
viru
iav
retain
abil
activ
mast
cell
suggest
occur
earli
viral
replic
cycl
mast
cell
abl
degranul
respons
dengu
viru
mast
cell
pretreat
antidengu
igg
demonstr
enhanc
degranul
respons
four
serotyp
dengu
viru
compar
dengu
viru
alon
suggest
antibodi
bind
enhanc
degranul
respons
dengu
viru
although
mast
cell
degranul
appear
pivot
immunopatholog
associ
highli
patholog
iav
dengu
viru
infect
understand
degranul
initi
date
viru
mechan
mast
cell
degranul
well
elucid
vaccinia
viru
activ
event
fusion
viral
envelop
mast
cell
plasma
membran
specif
vaccinia
viru
envelop
contain
sphingomyelin
convert
signal
gcoupl
receptor
caus
degranul
signal
also
shown
regul
mast
cell
respons
gener
howev
role
receptor
signal
viral
infect
remain
unknown
understand
molecular
signal
necessari
mast
cell
degranul
could
lead
novel
therapeut
avenu
highli
virul
viral
infect
predict
next
pandem
iav
strain
nearli
imposs
iav
high
mutat
rate
result
signific
yearli
antigen
drift
randomli
reassort
result
antigen
shift
even
decid
iav
strain
produc
yearli
vaccin
difficult
strain
must
chosen
month
ahead
yearli
influenza
season
predict
inaccur
season
iav
strain
drift
significantli
vaccin
highli
effect
result
high
incid
iavinduc
diseas
current
antivir
treatment
iav
becom
increasingli
ineffect
due
emerg
resist
strain
therefor
altern
therapeut
avenu
need
target
hostderiv
factor
necessari
viral
replic
host
factor
particip
excess
patholog
inflammatori
respons
highli
pathogen
iav
promis
altern
literatur
review
present
show
strong
correl
mast
cell
accumul
degranul
local
site
infect
observ
tissu
damag
patholog
highli
patholog
iav
infect
mani
pathogen
viral
infect
human
anim
addit
studi
examin
highli
patholog
virus
known
caus
ard
andor
vascular
leakag
thu
warrant
would
includ
emerg
coronavirus
sarscov
merscov
hemorrhag
virus
marburg
ebola
overal
hypothes
excess
mast
cell
activ
may
common
featur
highli
patholog
viral
infect
caus
ard
andor
vascular
leakag
novel
pathway
could
pharmacolog
target
limit
morbid
mortal
associ
infect
addit
understand
mast
cell
accumul
infect
tissu
mast
cell
prolifer
andor
mast
cell
progenitor
recruit
could
provid
addit
therapeut
target
figur
mast
cell
product
known
play
domin
role
allerg
asthmat
reaction
mani
drug
stabil
neutral
mast
cell
alreadi
approv
human
use
figur
mast
cell
stabil
drug
inhibit
releas
granul
follow
mast
cell
activ
proven
effect
reduc
vascular
leakag
limit
inflammatori
cellular
recruit
thu
increas
surviv
murin
dengu
viru
iav
model
furthermor
compound
proven
effect
limit
lung
patholog
follow
ibdv
ndv
poultri
compound
also
avail
block
activ
specif
mast
cell
product
includ
histamin
mast
cell
proteas
leukotrien
figur
mani
compound
alreadi
approv
treatment
inflammatori
arthriti
numer
antihistamin
includ
hydroxyzin
desloratadin
diphenhydramin
fexofenadin
loratadin
approv
treat
allergi
symptom
drug
current
develop
target
mast
cell
proteas
especi
mast
cell
deriv
chymas
implic
cardiovascular
diseas
final
two
class
leukotrien
antagonist
leukotrienereceptor
antagonist
zafirlukast
montelukast
leukotrien
synthesi
inhibitor
zileuton
addit
stand
alon
treatment
target
mast
cell
activ
mediat
adjunct
therapi
util
antivir
mast
cell
target
compound
might
fruit
earlier
studi
use
human
peripher
blood
leukocyt
expos
na
iav
time
ige
stimul
result
significantli
greater
histamin
releas
data
suggest
presenc
multipl
stimuli
may
result
addit
synergist
effect
therefor
mast
cell
target
drug
could
use
parallel
antivir
drug
greatest
efficaci
follow
infect
highli
pathogen
iav
strain
cohort
mice
surviv
infect
treat
antivir
mast
cell
stabil
compound
approach
may
prove
especi
benefici
asthmat
exacerb
follow
viral
infect
mast
cell
import
player
pathogen
defens
locat
environment
barrier
allow
quickli
respond
invad
pathogen
parasit
bacteri
infect
mast
cell
essenti
prevent
spread
infect
certain
viral
infect
mast
cell
protect
highli
pathogen
viral
infect
iav
system
dengu
infect
data
demonstr
mast
cell
detriment
benefici
role
mast
cell
iav
infect
highli
pathogen
viral
infect
elucid
cell
may
serv
lucr
target
new
therapeut
activ
releas
mediat
mast
cell
respons
virus
correl
sever
diseas
mice
applic
exist
allergi
medic
target
mast
cell
may
decreas
sever
iav
infect
limit
morbid
mortal
associ
futur
pandem
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
